Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity

American Journal of Hematology

Volumn 87, Issue 7, 2012, Pages 740-743

  Freeman, Andrew ^a   Horner, Tuesdy ^b   Pendleton, Robert C ^a   Rondina, Matthew T ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Presbyterian Hospital Albuquerque   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CREATININE; ENOXAPARIN;

ADULT; BLEEDING; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LETTER; LOW DRUG DOSE; LUNG EMBOLISM; MALE; MOLECULAR WEIGHT; OBESITY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; BED REST; BLOOD COAGULATION TESTS; BODY MASS INDEX; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FACTOR XA; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY, MORBID; PILOT PROJECTS; VENOUS THROMBOEMBOLISM;

EID: 84862527156     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23228     Document Type: Letter

References (23)

1. Freeman AL, Pendleton RC, Rondina MT. Prevention of venous thromboembolism in obesity. Expert Rev Cardiovasc Ther 2010, 8: 1711-1721.
2. Rondina MT, Pendleton RC, Wheeler M, Rodgers GM. The treatment of venous thromboembolism in special populations. Thromb Res 2007, 119: 391-402.
3. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. New Engl J Med 1999, 341: 793-800.
4. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133: 381S-453S.
5. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med 2005, 118: 978-980.
6. Ageno W, Squizzato A, Garcia D, Imberti D. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 2006, 32: 651-658.
7. Kanaan AO, Silva MA, Donovan JL, et al. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. Clin Ther 2007, 29: 2395-2405.
8. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000, 39: 215-231.
9. Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 2003, 90: 547-548.
10. Priglinger U, Delle Karth G, Geppert A, et al. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill? Crit Care Med 2003, 31: 1405-1409.
11. Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: Findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg 2005, 15: 1368-1374.
12. Ford ES, Mokdad AH. Epidemiology of obesity in the Western Hemisphere. J Clin Endocrinol Metab 2008, 93: S1-S8.
13. James WP. WHO recognition of the global obesity epidemic. Int J Obes (Lond) 2008, 32(Suppl 7): S120-S126.
14. Ludwig KP, Simons HJ, Mone M, et al. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. Ann Pharmacother 2011, 45: 1356-1362.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16: 31-41.
16. Martinez L, Burnett A, Borrego M, et al. Effect of fondaparinux prophylaxis on anti-Factor Xa concentrations in patients with morbid obesity. Am J Health Syst Pharm 2011, 68: 1716-1722.
17. Rondina MT, Wheeler M, Rodgers GM, et al. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thrombosis research 2010, 125: 220-223.
18. Sanderink GJ, Guimart CG, Ozoux ML, et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002, 105: 225-231.
19. Frydman A. Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996, 26(Suppl 2): 24-38.
20. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004, 110: 874-879.
21. Rocha AT, de Vasconcellos AG, da Luz Neto ER, et al. Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery. Obes Surg 2006, 16: 1645-1655.
22. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002, 12: 19-24.
23. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141: e495S-e530S.